Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 583Breast 330Sarcoma 207Other hematologic neoplasm 176Gynecologic 84Gastrointestinal 81Genitourinary 70CNS 60Plasma cell 51Thoracic 24Other solid neoplasm 24Dermatologic 15Endocrine 14Myeloid 12Head & Neck 12Tumor-Agnostic 11Classical hematology 4NET 2Other 1

Conditions

Neuroendocrine Tumors 2Neoplasms 2Neoplasm Metastasis 1

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Doxorubicin × NET × Clear all
NCT01678664 2024-09-25

EVACEL

Federation Francophone de Cancerologie Digestive

Phase 2 Completed
74 enrolled 10 charts
EndocrineNET

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡